Landanger Camus SA

Landanger Camus SA is a Paris-based company specializing in the fabrication and distribution of surgical instruments, primarily catering to the medical sector and enhancing surgical precision with its quality products. Founded in 1947 and headquartered in Paris, France, Landanger Camus SA fabricates and distributes surgical instruments for the medical sector. The company has not undergone any significant strategy pivots and operates independently without any notable parent or subsidiary relationships. The CEO, Benoit Landanger, has been instrumental in guiding the company's operations since its inception.

The company engaged in a funding round on May 9, 2019, when 21 Invest acquired a controlling stake, with Arkéa Capital also acquiring a minority stake in the company shortly thereafter. Landanger specializes in the fabrication and distribution of both reusable and single-use surgical instruments, primarily for the medical sector. The company collaborates with leading European manufacturers of orthopedic implants, utilizing over 40 years of industry experience to deliver high-quality medical devices. Their product range includes various surgical instruments, particularly in cardiovascular and thoracic applications under the renowned Delacroix-Chevalier brand, and emphasizes enhancing surgical precision and improving patient outcomes.

The firm’s commitment to quality is underscored by its ISO 13485 certification, validating adherence to international standards for medical devices. In 2018, Landanger reported a revenue of USD 30. 12 mn, generated through business-to-business transactions with healthcare providers and institutions. The company engages in direct sales to hospitals and surgical centers, offering a portfolio essential for various surgical procedures, often involving bulk orders of surgical instruments at competitive pricing.

Additionally, Landanger provides maintenance and repair services through its PETEL-Services division, enhancing customer retention and revenue stability. Landanger Camus SA aims to innovate by designing and launching new surgical instruments, with specific product launches expected in the coming years. The company plans to expand its market presence in Europe and potentially explore opportunities in North America by 2023. The funding secured in May 2019 will be strategically allocated to support these initiatives, enabling further growth and product development as well as enhancing operational capabilities.